Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 23;12(8):1198.
doi: 10.3390/jpm12081198.

The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review

Francesco Bonomi  1 , Silvia Peretti  1 , Gemma Lepri  1 , Vincenzo Venerito  2 , Edda Russo  1 , Cosimo Bruni  1   3 , Florenzo Iannone  2 , Sabina Tangaro  4 , Amedeo Amedei  1 , Serena Guiducci  1 , Marco Matucci Cerinic  1   5 , Silvia Bellando Randone  1
Affiliations
Review

The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review

Francesco Bonomi et al. J Pers Med. .

Abstract

Background: Systemic sclerosis (SSc) is a rare connective tissue disease that can affect different organs and has extremely heterogenous presentations. This complexity makes it difficult to perform an early diagnosis and a subsequent subclassification of the disease. This hinders a personalized approach in clinical practice. In this context, machine learning (ML), a branch of artificial intelligence (AI), is able to recognize relationships in data and predict outcomes.

Methods: Here, we performed a narrative review concerning the application of ML in SSc to define the state of art and evaluate its role in a precision medicine context.

Results: Currently, ML has been used to stratify SSc patients and identify those at high risk of severe complications. Additionally, ML may be useful in the early detection of organ involvement. Furthermore, ML might have a role in target therapy approach and in predicting drug response.

Conclusion: Available evidence about the utility of ML in SSc is sparse but promising. Future improvements in this field could result in a big step toward precision medicine. Further research is needed to define ML application in clinical practice.

Keywords: artificial intelligence; machine learning; precision medicine; systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overview of ML application in SSc to help in precision medicine.
See this image and copyright information in PMC

References

    1. Varga J., Trojanowska M., Kuwana M. Pathogenesis of systemic sclerosis: Recent insights of molecular and cellular mechanisms and therapeutic opportunities. J. Scleroderma Relat. Disord. 2017;2:137–152. doi: 10.5301/jsrd.5000249. - DOI
    1. Elhai M., Meune C., Boubaya M., Avouac J., Hachulla E., Balbir-Gurman A., Riemekasten G., Airò P., Joven B., Vettori S., et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum. Dis. 2017;76:1897–1905. doi: 10.1136/annrheumdis-2017-211448. - DOI - PubMed
    1. Toledano E., Candelas G., Rosales Z., Martínez Prada C., León L., Abásolo L., Loza E., Carmona L., Tobías A., Jover J.Á. A meta-analysis of mortality in rheumatic diseases. Reumatol. Clín. 2012;8:334–341. doi: 10.1016/j.reuma.2012.05.006. - DOI - PubMed
    1. Shand L., Lunt M., Nihtyanova S., Hoseini M., Silman A., Black C.M., Denton C.P. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model. Arthritis Rheum. 2007;56:2422–2431. doi: 10.1002/art.22721. - DOI - PubMed
    1. Bellando-Randone S., Galdo F.D., Lepri G., Minier T., Huscher D., Furst D.E., Allanore Y., Distler O., Czirják L., Bruni C., et al. Progression of patients with Raynaud’s phenomenon to systemic sclerosis: A five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS) Lancet Rheumatol. 2021;3:e834–e843. doi: 10.1016/S2665-9913(21)00244-7. - DOI - PubMed

LinkOut - more resources